



MATERNAL & CHILD HEALTH RESEARCH INSTITUTE

SEMINAR SERIES

The MCHRI SPARK Partnership: Designing Non-ototoxic Aminoglycosides

Monday, June 3, 2019 | 12:00pm - 1:00pm

Li Ka Shing Learning and Knowledge Center, Room #102



DARIA MOCHLY-ROSEN, PHD

Professor of Chemical & Systems Biology
Founder and Co-Director of SPARK

Recipient of MCHRI Cardiovascular Institute Award
and of Transdisciplinary Initiative Program Award

ALAN G. CHENG, MD

Associate Professor of Otolaryngology
(Head and Neck Surgery Divisions)

Recipient of Faculty Scholar Award

The Stanford Maternal and Child Health Research Institute (MCHRI) partners with the Stanford SPARK program to support innovative maternal and child health projects that will advance research discoveries into promising new treatments for patients. Hear from Dr. Daria Mochly-Rosen, founder and co-director of SPARK, provide a brief overview of the translational research program, mentoring and educational opportunities in drug development and commercialization, and resources available to participants of the program.

In this seminar, Dr. Alan Cheng, associate professor of otolaryngology and a SPARK scholar, will discuss his collaborative work with Dr. Anthony Ricci to create a safer drug version of aminoglycoside antibiotics – a commonly prescribed antibiotic that is one of the leading causes of hearing loss in children. With MCHRI and SPARK support, Dr. Cheng and his research team have developed the first series of antibiotic compounds and are testing the new version of non-ototoxic aminoglycoside antibiotics. He will present current research in this area, progress in the drug development stage, and the future direction of this work.

The seminars series is open to all, including faculty, staff, trainees, postdocs, and all members of the research community. Seats are limited, and reservation is required. Limited lunch will be provided on a first come, first served basis.

Register here: <https://mchri-seminar-jun3.eventbrite.com/>